Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news



To view this News Article

Similar stories

Since the family was named at MRC NIMR, publications have grown year on year

Crick alumnus Michael Geisow highlights his new review 'Annexin A1, A2, A5, and A6 involvement in human pathologies' pub… More...

Véronique Birault, Carola Vinuesa and Dominique Bonnet

Group leaders Carola Vinuesa and Dominique Bonnet, and Director of Translation, Véronique Birault, have been recognised … More...

Congratulations to Crick Group Leader and Associate Research Director, Julian Downward, who has been elected a Fellow of… More...

Ben Schumann has been awarded the Biochemical Society Early Career Research Award, recognising the impact of research ca… More...

Have your say


Contact us

The Francis Crick Institute
1 Midland Road

This website is powered by